Join Now

Author Archives: admin

Renalytix Expands US Government Coverage for FDA Approved kidneyintelX.dkd Testing at $950

Data to be Presented Today at NGS Open Meeting Demonstrating Clinical Value of KidneyIntelX LONDON and SALT LAKE CITY, February 29, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) announces that effective March 1, 2024, the United States Government has approved adding the company’s Food and Drug Administration (“FDA”) de Novo Marketing authorized test, kidneyintelX.dkd, to its […]

Posted in BioUtah News | Comments Off on Renalytix Expands US Government Coverage for FDA Approved kidneyintelX.dkd Testing at $950

Utah Legislative Recap, February 29, 2024

Funding Requests   Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create […]

Posted in BioUtah News | Comments Off on Utah Legislative Recap, February 29, 2024

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in […]

Posted in BioUtah News | Comments Off on Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Owlet Announces $9 Million Private Placement Financing

LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (NYSE: OWLT) (“Owlet” or the “Company”) announced today, following recent FDA clearances and strong preliminary fourth quarter results, that it has entered into definitive documentation relating to a sale of shares of its newly issued Series B convertible preferred stock (“Series B preferred stock”) and warrants to purchase its Class […]

Posted in BioUtah News | Comments Off on Owlet Announces $9 Million Private Placement Financing

PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

SALT LAKE CITY, Feb. 26, 2024 (GLOBE NEWSWIRE) — PolarityTE today announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 diabetic foot ulcers (DFUs), entitled “Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE II,” or “COVER DFUS II.” COVER DFUS […]

Posted in BioUtah News | Comments Off on PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

Utah Legislative Recap: February 23, 2024

Funding Requests Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create and […]

Posted in BioUtah News | Comments Off on Utah Legislative Recap: February 23, 2024

EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Novel Nanoparticle Platform Shows Efficacy Against Antimicrobial Resistance; Potential to Disrupt the $29 BillionCatheter Market SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ — EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world’s leading pathogens implicated […]

Posted in BioUtah News | Comments Off on EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience […]

Posted in BioUtah News | Comments Off on Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently Estimated to be Between $14.65and $15.35 per Share in the Late Spring or Early […]

Posted in BioUtah News | Comments Off on Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

PrecisionLife and Metrodora Institute Partner to Accelerate the Diagnosis and Treatment of Long COVID, ME/CFS, and other Chronic Conditions

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases Targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year   OXFORD, UK and SALT LAKE CITY, US – 15 February 2024 – The pioneering precision medicine company, […]

Posted in BioUtah News | Comments Off on PrecisionLife and Metrodora Institute Partner to Accelerate the Diagnosis and Treatment of Long COVID, ME/CFS, and other Chronic Conditions

Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses

The first patient undergoing wisdom tooth extraction has been dosed with HT-6184 to evaluate its effect on post-procedure diagnostic biomarkers of inflammation and pain, as well as to evaluate its safety and tolerability. LEHI, Utah, Feb. 15, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, […]

Posted in BioUtah News | Comments Off on Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses

Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System

New guidance system marks significant advancement in breast cancer care, targeting tumor location in multiple dimensions for precise excision and successful surgeries SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, has received US Food and Drug Administration (FDA) 501(k) clearance for the […]

Posted in BioUtah News | Comments Off on Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System